Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-05-27

AUTHORS

Kazuharu Kai, Nobuyuki Arima, Haruhiko Miyayama, Yutaka Yamamoto, Hirotaka Iwase, Reiki Nishimura

ABSTRACT

BackgroundNeoadjuvant chemotherapy (NAC) is the standard therapy for locally advanced breast cancer. Recently, several studies have revealed that clearance of axillary lymph node involvement is an independent factor for survival irrespective of the response of the primary lesion. However, in daily practice, it is difficult to fully examine every lymph node that has been surgically sampled, in view of pathology laboratory workload and cost. Therefore, in the present study, we adopted the more clinically relevant categorization of evaluating postoperative axillary lymph node status and retrospectively studied its significance in predicting patients’ survival.MethodsThe study cohort consisted of 35 locally advanced breast cancer patients who are treated with concomitant epirubicin–docetaxel. The clinicopathological factors used for analysis were as follows: ERα, PgR, p53, HER2, pathological response (in the primary tumor), and axillary lymph node status at surgery. With regard to axillary lymph node status, we categorized patients into two groups: those with pathological lymph node involvement at surgery (pLNI) and those without. Using multivariate analysis, we evaluated the significance of these factors in predicting disease-free survival after surgery.ResultsThe median follow-up period was 23.4 months (range 4.3–45.4). Multivariate analysis showed significantly reduced disease-free survival associated with pLNI (P = 0.005).ConclusionspLNI is an excellent prognostic factor for locally advanced breast cancer patients treated with concomitant epirubicin–docetaxel. Use of our criteria may enable large numbers of oncologists to participate in new studies of high-risk cohorts who are refractory to NAC. More... »

PAGES

42

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12282-008-0055-y

DOI

http://dx.doi.org/10.1007/s12282-008-0055-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1003257269

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18504642


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Axilla", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Ductal, Breast", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Lobular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Docetaxel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epirubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphatic Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multivariate Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoadjuvant Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Taxoids", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Koto, 862-8505, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan", 
            "Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Koto, 862-8505, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kai", 
        "givenName": "Kazuharu", 
        "id": "sg:person.01167266271.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167266271.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Pathology, Kumamoto City Hospital, 1-1-60 Koto, 862-8505, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Clinical Pathology, Kumamoto City Hospital, 1-1-60 Koto, 862-8505, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arima", 
        "givenName": "Nobuyuki", 
        "id": "sg:person.016542450374.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016542450374.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Pathology, Kumamoto City Hospital, 1-1-60 Koto, 862-8505, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Clinical Pathology, Kumamoto City Hospital, 1-1-60 Koto, 862-8505, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miyayama", 
        "givenName": "Haruhiko", 
        "id": "sg:person.01312777604.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312777604.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.274841.c", 
          "name": [
            "Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamamoto", 
        "givenName": "Yutaka", 
        "id": "sg:person.014073050404.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014073050404.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.274841.c", 
          "name": [
            "Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iwase", 
        "givenName": "Hirotaka", 
        "id": "sg:person.01117473535.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117473535.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Koto, 862-8505, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Koto, 862-8505, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nishimura", 
        "givenName": "Reiki", 
        "id": "sg:person.013173055502.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013173055502.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/bcr1510", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004693929", 
          "https://doi.org/10.1186/bcr1510"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2325/jbcs.13.38", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001814831", 
          "https://doi.org/10.2325/jbcs.13.38"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2325/jbcs.13.254", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020254423", 
          "https://doi.org/10.2325/jbcs.13.254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10147-006-0601-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001769831", 
          "https://doi.org/10.1007/s10147-006-0601-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-004-1001-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038578947", 
          "https://doi.org/10.1007/s10549-004-1001-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-05-27", 
    "datePublishedReg": "2008-05-27", 
    "description": "BackgroundNeoadjuvant chemotherapy (NAC) is the standard therapy for locally advanced breast cancer. Recently, several studies have revealed that clearance of axillary lymph node involvement is an independent factor for survival irrespective of the response of the primary lesion. However, in daily practice, it is difficult to fully examine every lymph node that has been surgically sampled, in view of pathology laboratory workload and cost. Therefore, in the present study, we adopted the more clinically relevant categorization of evaluating postoperative axillary lymph node status and retrospectively studied its significance in predicting patients\u2019 survival.MethodsThe study cohort consisted of 35 locally advanced breast cancer patients who are treated with concomitant epirubicin\u2013docetaxel. The clinicopathological factors used for analysis were as follows: ER\u03b1, PgR, p53, HER2, pathological response (in the primary tumor), and axillary lymph node status at surgery. With regard to axillary lymph node status, we categorized patients into two groups: those with pathological lymph node involvement at surgery (pLNI) and those without. Using multivariate analysis, we evaluated the significance of these factors in predicting disease-free survival after surgery.ResultsThe median follow-up period was 23.4\u00a0months (range 4.3\u201345.4). Multivariate analysis showed significantly reduced disease-free survival associated with pLNI (P\u00a0=\u00a00.005).ConclusionspLNI is an excellent prognostic factor for locally advanced breast cancer patients treated with concomitant epirubicin\u2013docetaxel. Use of our criteria may enable large numbers of oncologists to participate in new studies of high-risk cohorts who are refractory to NAC.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12282-008-0055-y", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1021080", 
        "issn": [
          "1340-6868", 
          "1880-4233"
        ], 
        "name": "Breast Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "keywords": [
      "advanced breast cancer patients", 
      "advanced breast cancer", 
      "disease-free survival", 
      "breast cancer patients", 
      "axillary lymph", 
      "pathological lymph", 
      "cancer patients", 
      "breast cancer", 
      "multivariate analysis", 
      "axillary lymph node involvement", 
      "axillary lymph node status", 
      "excellent prognostic factor", 
      "MethodsThe study cohort", 
      "lymph node involvement", 
      "lymph node status", 
      "high-risk cohort", 
      "significant predictive factors", 
      "BackgroundNeoadjuvant chemotherapy", 
      "median follow", 
      "neoadjuvant chemotherapy", 
      "node involvement", 
      "standard therapy", 
      "prognostic factors", 
      "cohort study", 
      "lymph nodes", 
      "study cohort", 
      "clinicopathological factors", 
      "primary lesion", 
      "node status", 
      "predictive factors", 
      "pathological response", 
      "independent factors", 
      "lymph", 
      "patients", 
      "surgery", 
      "daily practice", 
      "survival", 
      "chemotherapy", 
      "laboratory workload", 
      "cohort", 
      "cancer", 
      "present study", 
      "involvement", 
      "status", 
      "new studies", 
      "factors", 
      "recurrence", 
      "oncologists", 
      "HER2", 
      "therapy", 
      "lesions", 
      "ER\u03b1", 
      "follow", 
      "study", 
      "clearance", 
      "response", 
      "months", 
      "NAC", 
      "PgR", 
      "p53", 
      "significance", 
      "relevant categorization", 
      "group", 
      "plnI", 
      "period", 
      "criteria", 
      "analysis", 
      "large number", 
      "regard", 
      "use", 
      "practice", 
      "number", 
      "nodes", 
      "workload", 
      "categorization", 
      "view", 
      "cost"
    ], 
    "name": "Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin\u2013docetaxel neoadjuvant chemotherapy: a cohort study", 
    "pagination": "42", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1003257269"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12282-008-0055-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18504642"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12282-008-0055-y", 
      "https://app.dimensions.ai/details/publication/pub.1003257269"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-06-01T22:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_462.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12282-008-0055-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12282-008-0055-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12282-008-0055-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12282-008-0055-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12282-008-0055-y'


 

This table displays all metadata directly associated to this object as RDF triples.

280 TRIPLES      22 PREDICATES      128 URIs      115 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12282-008-0055-y schema:about N08e0700440434609894bffc6703c1308
2 N394cfd2b1622426a8e1725b7c96524cd
3 N425e57b2a4c643c786fbf28c451247a0
4 N475b7c14ac174684b7b88d5d07fa2a78
5 N492db919957142a5a8ce9a148b57639d
6 N5573908ba5ed4c488aa2d42b9d662417
7 N632833e6909a42438923a1ae5cd65cf2
8 N6f5c2de5ed35415dacb5d7a3d4ff7ed7
9 N7ccc39f79033447988960a18642fe8d2
10 N7ef402c8ae23490a856d979950c56b5c
11 N812480e6ad34468a90a64c8d80750fbe
12 N87b501bed435435cb74f04b1f4459ded
13 N8c178f712c064fcd8e8fdb99da8697c1
14 N97660e34545e4e88ad9dc2013b3974c5
15 Nab36bc036b1143f1bd6b046856b6a3fb
16 Naf840034ccdf4caf88cf120cb49a39e5
17 Nb4c6aeaa708441c0864a59e086fc4d07
18 Nbf99d54dfe6942378617149d9cdff011
19 Nc19bf2e9986c482f8f8416c984c03ef3
20 Ne94d5158af6a4d328002ed47ef901c97
21 anzsrc-for:11
22 anzsrc-for:1112
23 schema:author Nfeec2b459d284e91a41d78e4fa3db969
24 schema:citation sg:pub.10.1007/s10147-006-0601-6
25 sg:pub.10.1007/s10549-004-1001-0
26 sg:pub.10.1186/bcr1510
27 sg:pub.10.2325/jbcs.13.254
28 sg:pub.10.2325/jbcs.13.38
29 schema:datePublished 2008-05-27
30 schema:datePublishedReg 2008-05-27
31 schema:description BackgroundNeoadjuvant chemotherapy (NAC) is the standard therapy for locally advanced breast cancer. Recently, several studies have revealed that clearance of axillary lymph node involvement is an independent factor for survival irrespective of the response of the primary lesion. However, in daily practice, it is difficult to fully examine every lymph node that has been surgically sampled, in view of pathology laboratory workload and cost. Therefore, in the present study, we adopted the more clinically relevant categorization of evaluating postoperative axillary lymph node status and retrospectively studied its significance in predicting patients’ survival.MethodsThe study cohort consisted of 35 locally advanced breast cancer patients who are treated with concomitant epirubicin–docetaxel. The clinicopathological factors used for analysis were as follows: ERα, PgR, p53, HER2, pathological response (in the primary tumor), and axillary lymph node status at surgery. With regard to axillary lymph node status, we categorized patients into two groups: those with pathological lymph node involvement at surgery (pLNI) and those without. Using multivariate analysis, we evaluated the significance of these factors in predicting disease-free survival after surgery.ResultsThe median follow-up period was 23.4 months (range 4.3–45.4). Multivariate analysis showed significantly reduced disease-free survival associated with pLNI (P = 0.005).ConclusionspLNI is an excellent prognostic factor for locally advanced breast cancer patients treated with concomitant epirubicin–docetaxel. Use of our criteria may enable large numbers of oncologists to participate in new studies of high-risk cohorts who are refractory to NAC.
32 schema:genre article
33 schema:inLanguage en
34 schema:isAccessibleForFree false
35 schema:isPartOf Na04eaafa8d95460aa83c96a2c9f759d1
36 Nc931fd71d8ef43d38812f7ca2ae68e7c
37 sg:journal.1021080
38 schema:keywords BackgroundNeoadjuvant chemotherapy
39 ERα
40 HER2
41 MethodsThe study cohort
42 NAC
43 PgR
44 advanced breast cancer
45 advanced breast cancer patients
46 analysis
47 axillary lymph
48 axillary lymph node involvement
49 axillary lymph node status
50 breast cancer
51 breast cancer patients
52 cancer
53 cancer patients
54 categorization
55 chemotherapy
56 clearance
57 clinicopathological factors
58 cohort
59 cohort study
60 cost
61 criteria
62 daily practice
63 disease-free survival
64 excellent prognostic factor
65 factors
66 follow
67 group
68 high-risk cohort
69 independent factors
70 involvement
71 laboratory workload
72 large number
73 lesions
74 lymph
75 lymph node involvement
76 lymph node status
77 lymph nodes
78 median follow
79 months
80 multivariate analysis
81 neoadjuvant chemotherapy
82 new studies
83 node involvement
84 node status
85 nodes
86 number
87 oncologists
88 p53
89 pathological lymph
90 pathological response
91 patients
92 period
93 plnI
94 practice
95 predictive factors
96 present study
97 primary lesion
98 prognostic factors
99 recurrence
100 regard
101 relevant categorization
102 response
103 significance
104 significant predictive factors
105 standard therapy
106 status
107 study
108 study cohort
109 surgery
110 survival
111 therapy
112 use
113 view
114 workload
115 schema:name Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin–docetaxel neoadjuvant chemotherapy: a cohort study
116 schema:pagination 42
117 schema:productId N06e09daad70648f1b108835a4430feb4
118 N1717bae744a14ccc9f85ccad6d7b1190
119 N43a3aefcf98942ee8fe8f5f147b5f45a
120 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003257269
121 https://doi.org/10.1007/s12282-008-0055-y
122 schema:sdDatePublished 2022-06-01T22:08
123 schema:sdLicense https://scigraph.springernature.com/explorer/license/
124 schema:sdPublisher Nbf55a4d6323044468e2fedefe2bcc437
125 schema:url https://doi.org/10.1007/s12282-008-0055-y
126 sgo:license sg:explorer/license/
127 sgo:sdDataset articles
128 rdf:type schema:ScholarlyArticle
129 N06e09daad70648f1b108835a4430feb4 schema:name pubmed_id
130 schema:value 18504642
131 rdf:type schema:PropertyValue
132 N08e0700440434609894bffc6703c1308 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Adult
134 rdf:type schema:DefinedTerm
135 N129e256a2d864f04b741c0b8ef6b8f9d rdf:first sg:person.01117473535.84
136 rdf:rest N45412285abde44c387d976b420d0bd02
137 N1717bae744a14ccc9f85ccad6d7b1190 schema:name dimensions_id
138 schema:value pub.1003257269
139 rdf:type schema:PropertyValue
140 N1e113d30b130471fbb586614aad438d4 rdf:first sg:person.01312777604.01
141 rdf:rest N5724d8c7bf3844f2801880e3898a5f31
142 N394cfd2b1622426a8e1725b7c96524cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Breast Neoplasms
144 rdf:type schema:DefinedTerm
145 N3f77a45bc0b34125a56de3df6a4b4175 rdf:first sg:person.016542450374.76
146 rdf:rest N1e113d30b130471fbb586614aad438d4
147 N425e57b2a4c643c786fbf28c451247a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Carcinoma, Ductal, Breast
149 rdf:type schema:DefinedTerm
150 N43a3aefcf98942ee8fe8f5f147b5f45a schema:name doi
151 schema:value 10.1007/s12282-008-0055-y
152 rdf:type schema:PropertyValue
153 N45412285abde44c387d976b420d0bd02 rdf:first sg:person.013173055502.44
154 rdf:rest rdf:nil
155 N475b7c14ac174684b7b88d5d07fa2a78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Multivariate Analysis
157 rdf:type schema:DefinedTerm
158 N492db919957142a5a8ce9a148b57639d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Humans
160 rdf:type schema:DefinedTerm
161 N5573908ba5ed4c488aa2d42b9d662417 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Axilla
163 rdf:type schema:DefinedTerm
164 N5724d8c7bf3844f2801880e3898a5f31 rdf:first sg:person.014073050404.82
165 rdf:rest N129e256a2d864f04b741c0b8ef6b8f9d
166 N632833e6909a42438923a1ae5cd65cf2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Antineoplastic Combined Chemotherapy Protocols
168 rdf:type schema:DefinedTerm
169 N6f5c2de5ed35415dacb5d7a3d4ff7ed7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Epirubicin
171 rdf:type schema:DefinedTerm
172 N7ccc39f79033447988960a18642fe8d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Docetaxel
174 rdf:type schema:DefinedTerm
175 N7ef402c8ae23490a856d979950c56b5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Cohort Studies
177 rdf:type schema:DefinedTerm
178 N812480e6ad34468a90a64c8d80750fbe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Neoplasm Recurrence, Local
180 rdf:type schema:DefinedTerm
181 N87b501bed435435cb74f04b1f4459ded schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Neoadjuvant Therapy
183 rdf:type schema:DefinedTerm
184 N8c178f712c064fcd8e8fdb99da8697c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Middle Aged
186 rdf:type schema:DefinedTerm
187 N97660e34545e4e88ad9dc2013b3974c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Lymphatic Metastasis
189 rdf:type schema:DefinedTerm
190 Na04eaafa8d95460aa83c96a2c9f759d1 schema:volumeNumber 16
191 rdf:type schema:PublicationVolume
192 Nab36bc036b1143f1bd6b046856b6a3fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Taxoids
194 rdf:type schema:DefinedTerm
195 Naf840034ccdf4caf88cf120cb49a39e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Carcinoma, Lobular
197 rdf:type schema:DefinedTerm
198 Nb4c6aeaa708441c0864a59e086fc4d07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Antineoplastic Agents
200 rdf:type schema:DefinedTerm
201 Nbf55a4d6323044468e2fedefe2bcc437 schema:name Springer Nature - SN SciGraph project
202 rdf:type schema:Organization
203 Nbf99d54dfe6942378617149d9cdff011 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Female
205 rdf:type schema:DefinedTerm
206 Nc19bf2e9986c482f8f8416c984c03ef3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Disease-Free Survival
208 rdf:type schema:DefinedTerm
209 Nc931fd71d8ef43d38812f7ca2ae68e7c schema:issueNumber 1
210 rdf:type schema:PublicationIssue
211 Ne94d5158af6a4d328002ed47ef901c97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Retrospective Studies
213 rdf:type schema:DefinedTerm
214 Nfeec2b459d284e91a41d78e4fa3db969 rdf:first sg:person.01167266271.39
215 rdf:rest N3f77a45bc0b34125a56de3df6a4b4175
216 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
217 schema:name Medical and Health Sciences
218 rdf:type schema:DefinedTerm
219 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
220 schema:name Oncology and Carcinogenesis
221 rdf:type schema:DefinedTerm
222 sg:journal.1021080 schema:issn 1340-6868
223 1880-4233
224 schema:name Breast Cancer
225 schema:publisher Springer Nature
226 rdf:type schema:Periodical
227 sg:person.01117473535.84 schema:affiliation grid-institutes:grid.274841.c
228 schema:familyName Iwase
229 schema:givenName Hirotaka
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117473535.84
231 rdf:type schema:Person
232 sg:person.01167266271.39 schema:affiliation grid-institutes:grid.415532.4
233 schema:familyName Kai
234 schema:givenName Kazuharu
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167266271.39
236 rdf:type schema:Person
237 sg:person.01312777604.01 schema:affiliation grid-institutes:grid.415532.4
238 schema:familyName Miyayama
239 schema:givenName Haruhiko
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312777604.01
241 rdf:type schema:Person
242 sg:person.013173055502.44 schema:affiliation grid-institutes:grid.415532.4
243 schema:familyName Nishimura
244 schema:givenName Reiki
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013173055502.44
246 rdf:type schema:Person
247 sg:person.014073050404.82 schema:affiliation grid-institutes:grid.274841.c
248 schema:familyName Yamamoto
249 schema:givenName Yutaka
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014073050404.82
251 rdf:type schema:Person
252 sg:person.016542450374.76 schema:affiliation grid-institutes:grid.415532.4
253 schema:familyName Arima
254 schema:givenName Nobuyuki
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016542450374.76
256 rdf:type schema:Person
257 sg:pub.10.1007/s10147-006-0601-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001769831
258 https://doi.org/10.1007/s10147-006-0601-6
259 rdf:type schema:CreativeWork
260 sg:pub.10.1007/s10549-004-1001-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038578947
261 https://doi.org/10.1007/s10549-004-1001-0
262 rdf:type schema:CreativeWork
263 sg:pub.10.1186/bcr1510 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004693929
264 https://doi.org/10.1186/bcr1510
265 rdf:type schema:CreativeWork
266 sg:pub.10.2325/jbcs.13.254 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020254423
267 https://doi.org/10.2325/jbcs.13.254
268 rdf:type schema:CreativeWork
269 sg:pub.10.2325/jbcs.13.38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001814831
270 https://doi.org/10.2325/jbcs.13.38
271 rdf:type schema:CreativeWork
272 grid-institutes:grid.274841.c schema:alternateName Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan
273 schema:name Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan
274 rdf:type schema:Organization
275 grid-institutes:grid.415532.4 schema:alternateName Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Koto, 862-8505, Kumamoto, Japan
276 Clinical Pathology, Kumamoto City Hospital, 1-1-60 Koto, 862-8505, Kumamoto, Japan
277 schema:name Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, 860-8556, Kumamoto, Japan
278 Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Koto, 862-8505, Kumamoto, Japan
279 Clinical Pathology, Kumamoto City Hospital, 1-1-60 Koto, 862-8505, Kumamoto, Japan
280 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...